Managed Access Limits

Payers and health systems adopt Onswik cautiously because insulin is a cost-sensitive, mature category. The approval still matters strategically, but commercial uptake is slowed by prior authorization, step edits, and rebate negotiations.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.